Cargando…

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis

BACKGROUND: The Respiratory Syncytial Virus (RSV) Respiratory Events Among Preterm Infants Outcomes and Risk Tracking (REPORT) study evaluated RSV disease burden in US preterm infants 32–35 weeks gestational age (wGA) not receiving RSV prophylaxis. METHODS: Preterm infants <6 months of age as of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ambrose, Christopher S., Anderson, Evan J., Simões, Eric A. F., Wu, Xionghua, Elhefni, Hanaa, Park, C. Lucy, Sifakis, Frangiscos, Groothuis, Jessie R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Williams & Wilkins 2014
Materias:	Original Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025592/ https://www.ncbi.nlm.nih.gov/pubmed/24622396 http://dx.doi.org/10.1097/INF.0000000000000219

Ejemplares similares

Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32–35 Weeks Gestational Age
por: Franklin, Jeremy A., et al.
Publicado: (2016)

Correction: Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Immunoprophylaxis of respiratory syncytial virus: global experience
por: Simoes, Eric AF
Publicado: (2002)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Thyroid dysfunction in preterm infants born before 32 gestational weeks
por: Kim, Hye-Rim, et al.
Publicado: (2019)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Patient equity and respiratory syncytial virus Immunoprophylaxis
por: Cody Meissner, H.
Publicado: (2019)

Seasonality in Respiratory Syncytial Virus Hospitalizations and Immunoprophylaxis
por: Kusma, Jennifer D., et al.
Publicado: (2023)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

Bronchopulmonary Dysplasia in Preterm Infants Born at Less Than 32 Weeks Gestation
por: Xu, Yan-Ping
Publicado: (2016)

Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
por: Zuccotti, Gianvincenzo, et al.
Publicado: (2017)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
por: Kong, Amanda M., et al.
Publicado: (2018)

Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies
por: Lanari, M., et al.
Publicado: (2020)

Maturation of Paracetamol Elimination Routes in Preterm Neonates Born Below 32 Weeks of Gestation
por: Wu, Yunjiao, et al.
Publicado: (2023)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons
por: Anderson, Evan J., et al.
Publicado: (2017)

735. Severity and Healthcare Costs of Respiratory Syncytial Virus Hospitalizations in US Preterm Infants Born at 29–34 Weeks Gestation: 2014–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?
por: Sáfadi, Marco Aurélio P.
Publicado: (2014)

Long‐term renal follow up of preterm neonates born before 35 weeks of gestation
por: Horie, Akiyoshi, et al.
Publicado: (2019)

Neurodevelopmental Outcomes at 18 Months of Corrected Age for Late Preterm Infants Born at 34 and 35 Gestational Weeks
por: Nakasone, Ruka, et al.
Publicado: (2021)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
por: Rocca, Alessandro, et al.
Publicado: (2021)

The epidemiology and risk factors of respiratory syncytial virus and its impact on the timing of immunoprophylaxis
por: Jeena, Prakash Mohan
Publicado: (2018)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
por: Fang, Li-Ching, et al.
Publicado: (2023)

Antenatal magnesium sulfate treatment and risk of necrotizing enterocolitis in preterm infants born at less than 32 weeks of gestation
por: Hong, Ji Young, et al.
Publicado: (2020)

A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study
por: Simões, Eric AF, et al.
Publicado: (2008)

The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
por: Wong, Pierre C., et al.
Publicado: (2016)

Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis
por: Resch, B., et al.
Publicado: (2017)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Author Correction: Antenatal magnesium sulfate treatment and risk of necrotizing enterocolitis in preterm infants born at less than 32 weeks of gestation
por: Hong, Ji Young, et al.
Publicado: (2020)

Turning Foetal Breech Presentation at 32-35 Weeks of Gestational Age by Acupuncture and Moxibustion
por: Brici, Paolo, et al.
Publicado: (2019)

Evaluation of Preterm Delivery between 32(+0)-33(+6) Weeks of Gestation
por: Lee, Seung Soo, et al.
Publicado: (2008)

How can the occurrence of delayed elevation of thyroid stimulating hormone in preterm infants born between 35 and 36 weeks gestation be predicted?
por: Heo, You Jung, et al.
Publicado: (2019)

The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments
por: Makari, Doris, et al.
Publicado: (2015)

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017
por: Fergie, Jaime, et al.
Publicado: (2020)

An Institutional Approach to the Management of Asymptomatic Chorioamnionitis-Exposed Infants Born ≥35 Weeks Gestation
por: Chiruvolu, Arpitha, et al.
Publicado: (2019)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m4h0da4p42vsfj7rephmbt33s9